Eli Lilly & Co. (LLY) said that Effient, an oral antiplatelet agent, exhibited greater antiplatelet activity than high dose clopidogrel in Type 2 diabetes mellitus patients with coronary artery disease or CAD.
The OPTIMUS-3 or Third Optimizing anti-Platelet Therapy In Diabetes MellitUS study, which evaluated 35 patients with type 2 diabetes who also had CAD and were taking aspirin, showed that within four hours, the level of platelet inhibition as measured using the VerifyNow P2Y12 Test with a 60 mg loading dose of Effient was higher than observed with a 600 mg loading dose of clopidogrel.
The study also looked at the maintenance doses of Effient and clopidogrel. After seven days, results showed that a 10 mg maintenance dose of Effient achieved greater platelet inhibition than a 150 mg maintenance dose of clopidogrel.
Daiichi Sankyo Co. Ltd., and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries Ltd.
For comments and feedback: editorial@rttnews.com